241 related articles for article (PubMed ID: 22476202)
1. Using clinically approved cyclophosphamide regimens to control the humoral immune response to oncolytic viruses.
Peng KW; Myers R; Greenslade A; Mader E; Greiner S; Federspiel MJ; Dispenzieri A; Russell SJ
Gene Ther; 2013 Mar; 20(3):255-61. PubMed ID: 22476202
[TBL] [Abstract][Full Text] [Related]
2. Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamide.
Willmon C; Diaz RM; Wongthida P; Galivo F; Kottke T; Thompson J; Albelda S; Harrington K; Melcher A; Vile R
Mol Ther; 2011 Jan; 19(1):140-9. PubMed ID: 20978474
[TBL] [Abstract][Full Text] [Related]
3. Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus.
Galivo F; Diaz RM; Thanarajasingam U; Jevremovic D; Wongthida P; Thompson J; Kottke T; Barber GN; Melcher A; Vile RG
Hum Gene Ther; 2010 Apr; 21(4):439-50. PubMed ID: 19922169
[TBL] [Abstract][Full Text] [Related]
4. Amalgamating oncolytic viruses to enhance their safety, consolidate their killing mechanisms, and accelerate their spread.
Ayala-Breton C; Suksanpaisan L; Mader EK; Russell SJ; Peng KW
Mol Ther; 2013 Oct; 21(10):1930-7. PubMed ID: 23842448
[TBL] [Abstract][Full Text] [Related]
5. Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide.
Myers RM; Greiner SM; Harvey ME; Griesmann G; Kuffel MJ; Buhrow SA; Reid JM; Federspiel M; Ames MM; Dingli D; Schweikart K; Welch A; Dispenzieri A; Peng KW; Russell SJ
Clin Pharmacol Ther; 2007 Dec; 82(6):700-10. PubMed ID: 17971816
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the Impact of Oncolytic Vesicular Stomatitis Virus on the Trafficking, Phenotype, and Antigen Presentation Potential of Neutrophils and Their Ability to Acquire a Non-Structural Viral Protein.
Stegelmeier AA; Chan L; Mehrani Y; Petrik JJ; Wootton SK; Bridle B; Karimi K
Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32882969
[TBL] [Abstract][Full Text] [Related]
7. Re-engineering vesicular stomatitis virus to abrogate neurotoxicity, circumvent humoral immunity, and enhance oncolytic potency.
Muik A; Stubbert LJ; Jahedi RZ; Geiβ Y; Kimpel J; Dold C; Tober R; Volk A; Klein S; Dietrich U; Yadollahi B; Falls T; Miletic H; Stojdl D; Bell JC; von Laer D
Cancer Res; 2014 Jul; 74(13):3567-78. PubMed ID: 24812275
[TBL] [Abstract][Full Text] [Related]
8. Vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma.
Murphy AM; Besmer DM; Moerdyk-Schauwecker M; Moestl N; Ornelles DA; Mukherjee P; Grdzelishvili VZ
J Virol; 2012 Mar; 86(6):3073-87. PubMed ID: 22238308
[TBL] [Abstract][Full Text] [Related]
9. Vesicular stomatitis virus expressing interferon-β is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer.
Patel MR; Jacobson BA; Ji Y; Drees J; Tang S; Xiong K; Wang H; Prigge JE; Dash AS; Kratzke AK; Mesev E; Etchison R; Federspiel MJ; Russell SJ; Kratzke RA
Oncotarget; 2015 Oct; 6(32):33165-77. PubMed ID: 26431376
[TBL] [Abstract][Full Text] [Related]
10. Immunomodulation in Oncolytic Measles Virotherapy.
Dietz L; Engeland CE
Methods Mol Biol; 2020; 2058():111-126. PubMed ID: 31486034
[TBL] [Abstract][Full Text] [Related]
11. Smac mimetics and oncolytic viruses synergize in driving anticancer T-cell responses through complementary mechanisms.
Kim DS; Dastidar H; Zhang C; Zemp FJ; Lau K; Ernst M; Rakic A; Sikdar S; Rajwani J; Naumenko V; Balce DR; Ewanchuk BW; Tailor P; Yates RM; Jenne C; Gafuik C; Mahoney DJ
Nat Commun; 2017 Aug; 8(1):344. PubMed ID: 28839138
[TBL] [Abstract][Full Text] [Related]
12. Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor.
Jing Y; Tong C; Zhang J; Nakamura T; Iankov I; Russell SJ; Merchan JR
Cancer Res; 2009 Feb; 69(4):1459-68. PubMed ID: 19208845
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies.
Ong HT; Hasegawa K; Dietz AB; Russell SJ; Peng KW
Gene Ther; 2007 Feb; 14(4):324-33. PubMed ID: 17051248
[TBL] [Abstract][Full Text] [Related]
14. Safety Study: Intraventricular Injection of a Modified Oncolytic Measles Virus into Measles-Immune, hCD46-Transgenic, IFNαRko Mice.
Lal S; Peng KW; Steele MB; Jenks N; Ma H; Kohanbash G; Phillips JJ; Raffel C
Hum Gene Ther Clin Dev; 2016 Dec; 27(4):145-151. PubMed ID: 27604429
[TBL] [Abstract][Full Text] [Related]
15. Measles virus selectively blind to signaling lymphocyte activation molecule as a novel oncolytic virus for breast cancer treatment.
Sugiyama T; Yoneda M; Kuraishi T; Hattori S; Inoue Y; Sato H; Kai C
Gene Ther; 2013 Mar; 20(3):338-47. PubMed ID: 22717740
[TBL] [Abstract][Full Text] [Related]
16. Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-β.
Naik S; Nace R; Barber GN; Russell SJ
Cancer Gene Ther; 2012 Jul; 19(7):443-50. PubMed ID: 22522623
[TBL] [Abstract][Full Text] [Related]
17. Characteristics of oncolytic vesicular stomatitis virus displaying tumor-targeting ligands.
Ammayappan A; Peng KW; Russell SJ
J Virol; 2013 Dec; 87(24):13543-55. PubMed ID: 24089573
[TBL] [Abstract][Full Text] [Related]
18. Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.
Westcott MM; Liu J; Rajani K; D'Agostino R; Lyles DS; Porosnicu M
J Virol; 2015 Aug; 89(15):7944-54. PubMed ID: 25995245
[TBL] [Abstract][Full Text] [Related]
19. Prediction and validation of murine MHC class I epitopes of the recombinant virus VSV-GP.
Vijver SV; Danklmaier S; Pipperger L; Gronauer R; Floriani G; Hackl H; Das K; Wollmann G
Front Immunol; 2022; 13():1100730. PubMed ID: 36741416
[TBL] [Abstract][Full Text] [Related]
20. A modular self-adjuvanting cancer vaccine combined with an oncolytic vaccine induces potent antitumor immunity.
Das K; Belnoue E; Rossi M; Hofer T; Danklmaier S; Nolden T; Schreiber LM; Angerer K; Kimpel J; Hoegler S; Spiesschaert B; Kenner L; von Laer D; Elbers K; Derouazi M; Wollmann G
Nat Commun; 2021 Aug; 12(1):5195. PubMed ID: 34465781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]